Acupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung Cancer

This study will be an evaluation of the efficacy and safety of acupuncture to enhance the response rate of immunotherapy in advanced lung cancer. The main questions it aims to answer are 1. Does acupuncture heighten the response rate of immunotherapy in advanced lung cancer? 2. Does acupuncture heighten the safety of immunotherapy in advanced lung cancer? Researchers will compare acupuncture to sham acupuncture to see if acupuncture could enhance the response rate of immunotherapy in advanced lung cancer. Both groups will receive a standard anti-tumor Western medical treatment regimen (PD-1/PD

Trial Details

NCT ID
NCT06926140
Phase
NA
Sponsor
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Acupuncture
  • Sham Comparator
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

  • Age 18-75 years;
  • ECOG/PS score of grade 0-1 and expected survival ≥ 3 months;
  • Non-small cell lung cancer AJCC lung cancer staging of stage IIIB-IV, or small cell lung cancer staging of extensive stage;
  • PD-L1 immunohistochemistry detection of tumor cell positive proportion score (TPS) \<50%;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →